NASDAQ:SNY - Sanofi Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $108.83
  • Forecasted Upside: 116.89 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$50.18
▼ -0.83 (-1.63%)

This chart shows the closing price for SNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sanofi Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNY

Analyst Price Target is $108.83
▲ +116.89% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is $108.83, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 116.89% upside from the last price of $50.18.

This chart shows the closing price for SNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Sanofi. This rating has held steady since September 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2022UBS GroupBoost Price TargetBuy ➝ Buy€118.00 ➝ €119.00Low
5/23/2022SVB LeerinkInitiated CoverageOutperformMedium
5/2/2022GuggenheimBoost Price Target€121.00 ➝ €127.00Low
4/22/2022Morgan StanleyBoost Price Target€110.00 ➝ €112.00Low
4/14/2022BarclaysBoost Price Target€90.00 ➝ €105.00Low
4/8/2022UBS GroupLower Price TargetBuy ➝ Buy€122.00 ➝ €121.00Low
3/28/2022Morgan StanleyBoost Price Target€108.00 ➝ €110.00Medium
3/28/2022Credit Suisse GroupBoost Price Target€96.00 ➝ €105.00Low
3/28/2022Deutsche Bank AktiengesellschaftBoost Price Target€80.00 ➝ €85.00Low
2/28/2022Stifel NicolausInitiated CoverageBuyLow
1/25/2022Liberum CapitalUpgradeHold ➝ BuyMedium
11/1/2021HSBCUpgradeHold ➝ BuyLow
10/14/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
9/27/2021SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
8/12/2021UBS GroupReiterated RatingBuyLow
8/6/2021Morgan StanleyReiterated RatingOverweightMedium
7/30/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
4/30/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
4/29/2021BarclaysReiterated RatingEqual WeightLow
4/6/2021BarclaysReiterated RatingEqual WeightLow
2/10/2021Morgan StanleyReiterated RatingOverweightLow
1/19/2021UBS GroupReiterated RatingBuyLow
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageSellLow
1/8/2021Morgan StanleyReiterated RatingOverweightLow
11/3/2020Morgan StanleyReiterated RatingOverweightMedium
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
10/4/2020The Goldman Sachs GroupInitiated CoverageBuyMedium
9/29/2020Berenberg BankInitiated CoverageHoldLow
8/19/2020Stifel NicolausDowngradeBuy ➝ HoldLow
8/18/2020SVB LeerinkDowngradeMarket PerformLow
7/31/2020JPMorgan Chase & Co.Reiterated RatingOverweightMedium
6/9/2020Morgan StanleyReiterated RatingOverweightMedium
5/26/2020UBS GroupReiterated RatingBuyMedium
4/28/2020BarclaysReiterated RatingEqual WeightMedium
4/21/2020Morgan StanleyReiterated RatingOverweightMedium
3/17/2020BarclaysUpgradeUnderweight ➝ Equal WeightHigh
3/10/2020The Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
2/19/2020ArgusBoost Price TargetBuy$52.00 ➝ $56.00Low
2/11/2020SVB LeerinkInitiated CoverageMarket Perform$58.00Low
2/7/2020DZ BankReiterated RatingNeutralLow
1/22/2020Liberum CapitalDowngradeBuy ➝ HoldLow
1/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
12/6/2019BarclaysDowngradeEqual Weight ➝ UnderweightLow
11/13/2019ArgusReiterated RatingBuy$50.00 ➝ $52.00Low
10/14/2019JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/23/2019GuggenheimUpgradeNeutral ➝ BuyLow
9/20/2019Morgan StanleyUpgradeEqual ➝ Equal WeightMedium
9/3/2019Sanford C. BernsteinInitiated CoverageOutperform$52.00Low
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
8/14/2019UBS GroupUpgradeNeutral ➝ BuyHigh
8/6/2019JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/28/2019HC WainwrightReiterated RatingBuyLow
1/14/2019JPMorgan Chase & Co.Reiterated RatingNeutralMedium
12/14/2018Morgan StanleyInitiated CoverageEqual WeightLow
12/11/2018Jefferies Financial GroupUpgradeHold ➝ BuyLow
12/4/2018JPMorgan Chase & Co.Reiterated RatingNeutralMedium
11/30/2018UBS GroupReiterated RatingNeutralLow
11/8/2018ArgusBoost Price TargetBuy ➝ Buy$48.00 ➝ $50.00Low
11/1/2018BarclaysUpgradeUnderweight ➝ Equal WeightLow
10/31/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/23/2018Wolfe ResearchInitiated CoverageMarket PerformLow
10/15/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/10/2018Bank of AmericaUpgradeNeutral ➝ Buy$55.00Medium
8/24/2018ArgusBoost Price TargetBuy ➝ Buy$46.00 ➝ $48.00Low
8/10/2018CitigroupUpgradeNeutral ➝ BuyHigh
8/1/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
8/1/2018BNP ParibasUpgradeNeutral ➝ OutperformLow
7/31/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/16/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
3/23/2018Liberum CapitalUpgradeHold ➝ BuyLow
3/12/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
2/8/2018Sanford C. BernsteinReiterated RatingMarket Perform$50.00 ➝ $45.00Low
1/23/2018BarclaysDowngradeEqual Weight ➝ UnderweightLow
1/15/2018UBS GroupReiterated RatingNeutralLow
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/2/2018Nord/LBReiterated RatingNeutralLow
12/27/2017Nord/LBReiterated RatingNeutralLow
12/18/2017CowenSet Price TargetHold$48.00Low
12/14/2017JPMorgan Chase & Co.Reiterated RatingNeutralHigh
12/6/2017Bank of AmericaDowngradeBuy ➝ NeutralLow
12/1/2017Morgan StanleyDowngradeOverweight ➝ UnderweightLow
11/15/2017BarclaysUpgradeUnderweight ➝ Equal WeightN/A
9/15/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/1/2017ArgusReiterated RatingBuy$55.00Medium
8/1/2017CowenReiterated RatingMarket Perform$46.00 ➝ $52.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
12/7/2021
  • 4 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/5/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
4/6/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
6/5/2022
  • 7 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 7 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Sanofi logo
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read More

Today's Range

Now: $50.18
Low: $49.56
High: $50.28

50 Day Range

MA: $52.27
Low: $48.99
High: $56.29

52 Week Range

Now: $50.18
Low: $46.92
High: $58.10

Volume

1,491,505 shs

Average Volume

2,191,960 shs

Market Capitalization

$126.82 billion

P/E Ratio

16.24

Dividend Yield

2.47%

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Sanofi?

The following Wall Street sell-side analysts have issued stock ratings on Sanofi in the last twelve months: Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, HSBC Holdings plc, JPMorgan Chase & Co., Liberum Capital, Morgan Stanley, Stifel Nicolaus, SVB Leerink LLC, and UBS Group AG.
View the latest analyst ratings for SNY.

What is the current price target for Sanofi?

0 Wall Street analysts have set twelve-month price targets for Sanofi in the last year. Their average twelve-month price target is $108.83, suggesting a possible upside of 116.9%.
View the latest price targets for SNY.

What is the current consensus analyst rating for Sanofi?

Sanofi currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNY will outperform the market and that investors should add to their positions of Sanofi.
View the latest ratings for SNY.

How do I contact Sanofi's investor relations team?

Sanofi's physical mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company's listed phone number is (315) 377-4000 and its investor relations email address is [email protected] The official website for Sanofi is www.sanofi.com. Learn More about contacing Sanofi investor relations.